Methods for treating irritable bowel syndrome (ibs)

Abstract

The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.

1 - 36 . (canceled) 
     
     
         37 . A method of treating one or more symptoms of irritable bowel syndrome (IBS) in a subject 65 years of age or older, said method comprising administering 550 mg of rifaximin TID to the subject, thereby treating one ore more symptoms of IBS in the subject 65 years of age or older. 
     
     
         38 . The method of  claim 37 , wherein the one or more symptoms are selected from one or more of cramping, pain, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and urgency. 
     
     
         39 . The method of  claim 37 , wherein the IBS is diarrhea-predominant IBS. 
     
     
         40 . The method of  claim 37 , wherein the IBS is alternating IBS. 
     
     
         41 . The method of  claim 37 , wherein the treating one or more symptoms of IBS comprises a reduction of the one or more symptoms from baseline symptoms established prior to treatment. 
     
     
         42 . The method of  claim 41 , wherein the reduction of the one or more symptoms is achieved following 7 days after the administration of rifaximin. 
     
     
         43 . The method of  claim 37 , wherein treating one or more symptoms of IBS comprises a reduction in symptoms defined by an affirmative response from the subject when asked whether they had a reduction in symptoms of IBS. 
     
     
         44 . A method of treating bloating associated with diarrhea-predominant IBS in a subject 65 years old or older, said method comprising administering 550 mg of rifaximin TID to the subject, thereby treating bloating associated with diarrhea-predominant IBS in the subject 65 years old or older. 
     
     
         45 . The method of  claim 44 , wherein the treating of bloating comprises a reduction of bloating. 
     
     
         46 . The method of  claim 45 , wherein the reduction of bloating is achieved following 7 days of the administration of the rifaximin. 
     
     
         47 . The method of  claim 45 , wherein the reduction of bloating comprises an affirmative response from a subject if asked whether they have had a reduction in bloating. 
     
     
         48 . The method of  claim 44 , further comprising treating one or more symptoms associated with diarrhea-predominant IBS selected from cramping, pain, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, urgency, and tenesmus. 
     
     
         49 . The method of  claim 45 , wherein the reduction in bloating is a reduction as compared with baseline. 
     
     
         50 . The method of  claim 49 , wherein baseline is established prior to treatment. 
     
     
         51 . The method of  claim 50 , wherein the reduction in bloating is achieved following 7 days of the administration of the rifaximin. 
     
     
         52 . The method of  claim 51 , wherein the reduction in bloating comprises an affirmative response from a subject if asked whether they have had a reduction in bloating.